LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Abbott Laboratories

Closed

SectorHealthcare

132.72 3.36

Overview

Share price change

24h

Current

Min

127.94

Max

132.85

Key metrics

By Trading Economics

Income

-7.9B

1.3B

Sales

-616M

10B

P/E

Sector Avg

17.142

56.602

EPS

1.09

Dividend yield

1.76

Profit margin

12.792

Employees

114,000

EBITDA

-324M

2.7B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.89% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.76%

2.45%

Next Dividend date

15 May 2025

Next Ex Dividend date

14 Jul 2025

Market Stats

By TradingEconomics

Market Cap

1.8B

230B

Previous open

129.36

Previous close

132.72

News Sentiment

By Acuity

40%

60%

141 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Abbott Laboratories Chart

Past performance is not a reliable indicator of future results.

Related News

16 Apr 2025, 16:21 UTC

Earnings

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 Apr 2025, 12:14 UTC

Earnings

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22 Jan 2025, 19:03 UTC

Earnings

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22 Jan 2025, 18:20 UTC

Earnings

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22 Jan 2025, 12:45 UTC

Earnings

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16 Apr 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 Apr 2025, 14:17 UTC

Earnings

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 Apr 2025, 11:34 UTC

Earnings

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 Apr 2025, 11:33 UTC

Earnings

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 Apr 2025, 11:32 UTC

Earnings

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 Apr 2025, 11:32 UTC

Earnings

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 Apr 2025, 11:31 UTC

Earnings

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 Apr 2025, 11:30 UTC

Earnings

Abbott Reaffirms Full-Yr Guidance

16 Apr 2025, 11:30 UTC

Earnings

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 Apr 2025, 11:30 UTC

Earnings

Abbott Labs 1Q Sales $10.36B >ABT

16 Apr 2025, 11:30 UTC

Earnings

Abbott Labs 1Q Net $1.33B >ABT

16 Apr 2025, 11:30 UTC

Earnings

Abbott Labs 1Q EPS 76c >ABT

16 Apr 2025, 11:30 UTC

Earnings

Abbott Labs 1Q Adj EPS $1.09 >ABT

16 Apr 2025, 09:57 UTC

Hot Stocks

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1 Feb 2025, 18:14 UTC

Top News

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22 Jan 2025, 16:40 UTC

Top News
Earnings

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22 Jan 2025, 15:20 UTC

Earnings

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22 Jan 2025, 15:08 UTC

Earnings

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 Jan 2025, 13:51 UTC

Earnings

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22 Jan 2025, 13:39 UTC

Top News
Earnings

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22 Jan 2025, 12:02 UTC

Earnings

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22 Jan 2025, 12:01 UTC

Earnings

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22 Jan 2025, 12:01 UTC

Earnings

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22 Jan 2025, 12:00 UTC

Earnings

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22 Jan 2025, 12:00 UTC

Earnings

Abbott Labs 4Q Net $9.23B >ABT

Peer Comparison

Price change

Abbott Laboratories Forecast

Price Target

By TipRanks

11.89% upside

12 Months Forecast

Average 144.4 USD  11.89%

High 159 USD

Low 127 USD

Based on 21 Wall Street analysts offering 12 month price targets forAbbott Laboratories - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

18

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

132.82 / 134.43Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

141 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.